Blog
RSS FeedPosted by Michael Wonder on 22 Aug 2016
Lilly and AstraZeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer's disease
22 August 2016 - AZD3293 is an oral potent small molecule BACE inhibitor in phase 3 development. ...